A Phase II-III, Multicentre, Prospective, Exploratory, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120mg in the Symptomatic Treatment of Patients With Refractory Diarrhoea

Trial Profile

A Phase II-III, Multicentre, Prospective, Exploratory, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120mg in the Symptomatic Treatment of Patients With Refractory Diarrhoea

Completed
Phase of Trial: Phase II/III

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Diarrhoea
  • Focus Therapeutic Use
  • Acronyms MEDARD
  • Sponsors Ipsen
  • Most Recent Events

    • 13 Jul 2016 Results published in the Clinical Therapeutics
    • 28 Mar 2014 New trial record
    • 07 Oct 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top